VS003

VS003 is an investigational drug candidate being developed by Vigorous Solutions, a subsidiary of the Drug Rediscovery Group, for the treatment of pulmonary hypertensive crisis. VS003 is a specialized formulation of sildenafil, a selective inhibitor of phosphodiesterase type 5 (PDE5). By inhibiting the breakdown of cyclic guanosine monophosphate (cGMP), sildenafil promotes nitric oxide-mediated vasodilation in the pulmonary vasculature, thereby reducing pulmonary arterial pressure. While sildenafil is well-established for chronic pulmonary arterial hypertension (as Revatio) and erectile dysfunction (as Viagra), VS003 is specifically designed for acute, emergency settings. The development of VS003 focuses on a rapid-acting delivery method, likely via inhalation, to provide immediate relief during a crisis while minimizing systemic side effects such as hypotension.

Other names

Inhaled sildenafil